KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)

類似資料

• Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
  著者:: Gonsalves, Wilson I., 等
  出版事項: (2014)
• Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
  著者:: Sinicrope, Frank A., 等
  出版事項: (2015)
• Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients
  著者:: Yoon, Harry H., 等
  出版事項: (2015)
• Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147
  著者:: Huang, Jocelin, 等
  出版事項: (2013)
• Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
  著者:: Singh, Preet Paul, 等
  出版事項: (2016)